Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Depreciation and DepletionExchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeOther Working Capital ChangesShare-based Compensation
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Vanda Pharmaceuticals (VNDA) Free Cash Flow: 2010-2025

Historic Free Cash Flow for Vanda Pharmaceuticals (VNDA) over the last 15 years, with Sep 2025 value amounting to -$31.8 million.

  • Vanda Pharmaceuticals' Free Cash Flow fell 115.62% to -$31.8 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$83.0 million, marking a year-over-year decrease of 355.76%. This contributed to the annual value of -$16.2 million for FY2024, which is 230.83% down from last year.
  • As of Q3 2025, Vanda Pharmaceuticals' Free Cash Flow stood at -$31.8 million, which was down 104.40% from -$15.6 million recorded in Q2 2025.
  • Over the past 5 years, Vanda Pharmaceuticals' Free Cash Flow peaked at $31.8 million during Q1 2023, and registered a low of -$33.6 million during Q1 2025.
  • For the 3-year period, Vanda Pharmaceuticals' Free Cash Flow averaged around -$7.7 million, with its median value being -$7.0 million (2024).
  • Per our database at Business Quant, Vanda Pharmaceuticals' Free Cash Flow surged by 808.05% in 2021 and then slumped by 610.80% in 2024.
  • Over the past 5 years, Vanda Pharmaceuticals' Free Cash Flow (Quarterly) stood at $26.5 million in 2021, then slumped by 65.43% to $9.2 million in 2022, then crashed by 143.54% to -$4.0 million in 2023, then spiked by 49.03% to -$2.0 million in 2024, then plummeted by 115.62% to -$31.8 million in 2025.
  • Its Free Cash Flow was -$31.8 million in Q3 2025, compared to -$15.6 million in Q2 2025 and -$33.6 million in Q1 2025.